Approximately 6 weeks prior to the proposed treatment, the patient will begin an 
appropriate diet (AHA phase III) and will withdraw all drugs that may interfere with 
lipoprotein metabolism. Traditional forms of therapy to lower cholesterol such as drugs, 
plasmapheresis, or LDL apheresis will be withheld for 6 weeks prior to and 6 weeks after the 
treatment. 
Baseline metabolic parameters will be determined by a review of the hospital record as 
well as the initial evaluation to be performed 4 weeks prior to the procedure (see Sect III.B.). 
Lipid/lipoprotein profiles (cholesterol, triglycerides, HDL-C and LDL-C) will be determined 
biweekly for a 3 week period between the initial evaluation and the hospital admission for the 
treatment. Summarized below are the analyses to be performed during the hospitalization. 
Admitting evaluation (a subset of the preliminary evaluation described in Section III.B.) 
History and physical exam 
General laboratory studies: 
CBC, platelets 
Erythrocyte sedimentation rate (ESR) 
Complete urinalysis 
Test panel II 
Test panel IV 
Assess liver function; see above 
Assess coagulation status: 
Prothrombin time 
Partial thromboplastin time 
Assess lipid/lipoprotein status: 
Fasting cholesterol, triglycerides, HDL-C, LDL-C 
Lipoprotein electrophoresis 
LPP fractionation 
C-HDL & TG in LDL, IDL, VLDL, HDL, and chylos 
Assess other atherogenic potentials: 
Fibrinogen 
PAI 
LP(a) 
Cardiac evaluation: 
Chest X-ray 
EKG 
Cardiology consult 
Evaluation for 7 days prior to liver resection. 
Daily fasting cholesterol, triglycerides, HDL-C, LDL-C 
Evaluation for 10 days after liver resection 
Daily fasting cholesterol, triglycerides, HDL-C, LDL-C 
Daily EKG 
Every other day liver function tests 
Every other day CBC 
Evaluation following discharge from hospital. 
Fasting cholesterol, triglycerides, HDL-C, LDL-C to be performed 
Biweekly- first month 
[188] 
Recombinant DNA Research, Volume 15 
